PURPOSE: Acute gastrointestinal syndrome (AGS) resulting from ionizing radiation causes death within 7 days. Currently, no satisfactory agent exists for mitigation of AGS. A peptide derived from the receptor binding domain of fibroblast growth factor 2 (FGF-P) was synthesized and its mitigation effect on AGS was examined. METHODS AND MATERIALS: A subtotal body irradiation (sub-TBI) model was created to induce gastrointestinal (GI) death while avoiding bone marrow death. After 10.5 to 16 Gy sub-TBI, mice received an intramuscular injection of FGF-P (10 mg/kg/day) or saline (0.2 ml/day) for 5 days; survival (frequency and duration) was measured. Crypt cells and their proliferation were assessed by hematoxylin, eosin, and BrdU staining. In addition, GI hemoccult score, stool formation, and plasma levels of endotoxin, insulin, amylase, interleukin (IL)-6, keratinocyte-derived chemokine (KC) monocyte chemoattractant protein 1 (MCP-1) and tumor necrosis factor (TNF)-alpha were evaluated. RESULTS: Treatment with FGF-P rescued a significant fraction of four strains of mice (33-50%) exposed to a lethal dose of sub-TBI. Use of FGF-P improved crypt survival and repopulation and partially preserved or restored GI function. Furthermore, whereas sub-TBI increased plasma endotoxin levels and several pro-inflammation cytokines (IL-6, KC, MCP-1, and TNF-alpha), FGF-P reduced these adverse responses. CONCLUSIONS: The study data support pursuing FGF-P as a mitigator for AGS.
PURPOSE:Acute gastrointestinal syndrome (AGS) resulting from ionizing radiation causes death within 7 days. Currently, no satisfactory agent exists for mitigation of AGS. A peptide derived from the receptor binding domain of fibroblast growth factor 2 (FGF-P) was synthesized and its mitigation effect on AGS was examined. METHODS AND MATERIALS: A subtotal body irradiation (sub-TBI) model was created to induce gastrointestinal (GI) death while avoiding bone marrow death. After 10.5 to 16 Gy sub-TBI, mice received an intramuscular injection of FGF-P (10 mg/kg/day) or saline (0.2 ml/day) for 5 days; survival (frequency and duration) was measured. Crypt cells and their proliferation were assessed by hematoxylin, eosin, and BrdU staining. In addition, GI hemoccult score, stool formation, and plasma levels of endotoxin, insulin, amylase, interleukin (IL)-6, keratinocyte-derived chemokine (KC) monocyte chemoattractant protein 1 (MCP-1) and tumor necrosis factor (TNF)-alpha were evaluated. RESULTS: Treatment with FGF-P rescued a significant fraction of four strains of mice (33-50%) exposed to a lethal dose of sub-TBI. Use of FGF-P improved crypt survival and repopulation and partially preserved or restored GI function. Furthermore, whereas sub-TBI increased plasma endotoxin levels and several pro-inflammation cytokines (IL-6, KC, MCP-1, and TNF-alpha), FGF-P reduced these adverse responses. CONCLUSIONS: The study data support pursuing FGF-P as a mitigator for AGS.
Authors: D B Pateder; R A Eliseev; R J O'Keefe; E M Schwarz; P Okunieff; L S Constine; J E Puzas; R N Rosier Journal: Radiat Res Date: 2001-06 Impact factor: 2.841
Authors: Jerzy G Maj; François Paris; Adriana Haimovitz-Friedman; Ennapadam Venkatraman; Richard Kolesnick; Zvi Fuks Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Jiangwei Li; Ghada S Hassan; Terence M Williams; Carlo Minetti; Richard G Pestell; Herbert B Tanowitz; Philippe G Frank; Federica Sotgia; Michael P Lisanti Journal: Cell Cycle Date: 2005-12-22 Impact factor: 4.534
Authors: Pavel Krejci; Bernard Masri; Vincent Fontaine; Pertchoui B Mekikian; Maryann Weis; Herve Prats; William R Wilcox Journal: J Cell Sci Date: 2005-10-18 Impact factor: 5.285
Authors: Martee L Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; Gary I Cohen; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel von Hoff; Lynn M Schuchter Journal: J Clin Oncol Date: 2008-11-17 Impact factor: 44.544
Authors: Julie M Sullivan; Laura B Jeffords; Chang-Lung Lee; Rafaela Rodrigues; Yan Ma; David G Kirsch Journal: Radiat Res Date: 2011-12-13 Impact factor: 2.841
Authors: Michael M Fisher; Gopika SenthilKumar; Rong Hu; Steve Goldstein; Irene M Ong; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Lindsey Abel; Kwangok P Nickel; Gopal Iyer; Paul M Harari; Randall J Kimple; Andrew M Baschnagel Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-13 Impact factor: 7.038
Authors: Kenneth J Janec; Huaiping Yuan; James E Norton; Rowan H Kelner; Christian K Hirt; Rebecca A Betensky; Eva C Guinan Journal: Am J Hematol Date: 2018-05-11 Impact factor: 10.047
Authors: Gopika SenthilKumar; Michael M Fisher; Justin H Skiba; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Samantha T Bradley; Colin A Longhurst; Darya Buehler; Kwangok P Nickel; Gopal Iyer; Randall J Kimple; Andrew M Baschnagel Journal: Mol Cancer Ther Date: 2020-05-05 Impact factor: 6.261
Authors: Andrea L DiCarlo; Zulmarie Perez Horta; Carmen I Rios; Merriline M Satyamitra; Lanyn P Taliaferro; David R Cassatt Journal: Int J Radiat Biol Date: 2020-09-24 Impact factor: 2.694